Candida species are the most important microorganisms implicated in fungal infections as major causes of morbidity and mortality which could be attributed mainly to increased susceptibility of individuals to infection due to immune-suppression and invasive drug therapy [1] . The growing problem of mucosal and systemic candidiasis reflects the enormous increase in the number of patients at risk and the increased opportunity that exists for Candida species to invade deep tissues [1] . Candida species can cause infections under altered physiological and pathological conditions, which are difficult to treat and tend to recur [2] . The increased prevalence of local and systemic disease caused by Candida species has resulted in numerous new clinical syndromes. Candida species produce a wide spectrum of diseases, ranging from superficial mucocutaneous disease to invasive illnesses, such as hepatosplenic candidiasis, Candida peritonitis, and systemic candidiasis [3] . Several local and systemic host factors, particularly impaired immunity, can facilitate opportunistic infection by Candida species [4] . In addition, management of Candida infections faces a number of problems, including limited numbers of effective anti-fungal drugs, a high relapse rate, expensive antimycotic drug therapy, toxic side effects, and occurrence of resistance to available antifungal drugs [5] [6] [7] [8] .
Bioconversion is a ''green'' technology that converts the substrate products into entirely new chemical compounds with antimicrobial, industrial and biomedical properties. The production of bioconverted products using potent bacterial strains could be a necessary step in the successful application of microbial technology and to develop a wide range of microbial products for their therapeutic uses. The bioconversion reactions using bacterial strains have been cited extensively among microbial systems that produce potent microbial products with enhanced biological efficacy. A number of microbially bioconverted products have been shown to suppress the growth of harmful microbes, including Candida species [9, 10] . Although the production of antifungal agents through bioconversion by microorganisms has been confirmed previously [11] , microbially bioconverted products of vegetables using bacterial species are being investigated as possible alternatives for the production of complementary therapeutic compounds to treat serious fungal infections caused by Candida species.
In this study, we report for the first time the microbial conversion of tomato by a plant pathogenic bacterium Pectobacterium atrosepticum. Using the microbially bioconverted products of tomato, we determined their efficacy as a potential antimycotic agent against several pathogenic and clinical isolates of Candida species.
The antimycotic effect of the bioconverted products of tomato against the employed isolates of Candida species was monitored by the diameter of inhibition zones. The bioconverted products (500 μg/disc) exhibited potent inhibitory effects (Table 1) . C. albicans KBN06P00566, C. glabrata KBN06P00368 and C. albicans KACC 30004 were found to be the most inhibited fungal pathogens by the bioconverted products, with respective diameter of zones of inhibition of 14 ± 0.4, 13 ± 0.5 and 12 ± 0.4 mm, whereas the values for the bioconverted products against C. albicans KBN06P00565, C. albicans KACC 30062 and C. albicans KCTC 7270 were 11 ± 0.6, 10 ± 0.7 and 9 ± 0.6 mm, respectively ( Table  1) . The negative controls, [solvent; tomato supernatants (fresh crushed tomato, and 7 days fermented tomato); as well as bacterial supernatants of P. atrosepticum (24 9 ± 0.6d 12 ± 0.8bc x Diameter of inhibition zones of bioconverted products of tomato by P. atrosepticum (tested volume: 500 μg/disc); y Standard antibiotic amphotericin B (10 μg/disc); z Values followed by the same letter are not significantly different (p > 0.05). Supernatants from tomato fruits (fresh and 7 days old fermented) and P. atrosepticum (24 h and 7 day cultures) had no antimycotic effect. antifungal effect. It was found that the bioconverted products of tomato significantly inhibited the growth of both clinical and laboratory isolates of Candida species. As a positive control, the antibiotic amphotericin B provoked a higher antifungal effect (diameter of zones of inhibition: 11 ± 0.7 to 16 ± 0.3 mm) than that of the bioconverted products. However, the growth of the clinical isolate of C. glabrata KBN06P00368 was severely inhibited by the bioconverted products compared with amphotericin B (Table 1) .
Previously it has been reported that several bioconverted products possess potent antifungal effect against harmful pathogens, including Candida species [9, 10, 12] . Certain extracts and/or compounds as bioconverted products display an antifungal effect in many ways on various types of disease complex, and may be applied as a bioformulation in the same way against either pathogenic or clinical isolates of Candida species as alternative biomedicinal products. Candida infections are getting serious worldwide due to the pathogenic disorders in human beings, although control measures are available, but of limited effectiveness [13] . Hence, microbial conversion of vegetable products using efficient microbial strains can be considered as an alternative biotechnological approach to develop novel types of antimycotic agents.
The MIC and MFC values of the bioconverted products of tomato against the tested clinical and laboratory isolates of Candida were in the range of 250 to 1000 and 250 to 2000 μg/mL, respectively ( Table 2) , whereas the MIC values of amphotericin B against the tested isolates of Candida were found in the range of 15.6 to 125 μg/mL. C. albicans KACC 30004 and C. albicans KBN06P00566 were found to be less sensitive to amphotericin B when compared with the other tested isolates. On the other hand, C. albicans KBN06P00566 and C. glabrata KBN06P00368 were found to be the most susceptible fungal species to the bioconverted products with a MIC value of 250 μg/mL for each fungal pathogen, followed by C. albicans KBN06P00565 (MIC: 500 μg/mL), C. albicans KACC 30062 (MIC: 500 μg/mL), C. albicans KACC 30004 (MIC: 500 μg/mL), and C. albicans KCTC 7270 (MIC: 1000 μg/mL). As reported previously, the bioconverted products obtained from the microbial conversion of vegetables using different microbial strains showed potent antimycotic effects against the tested Candida pathogens [9, 12] .
It was also described in this study that the bioconverted products of tomato had a complex effect on cell viable counts of the tested isolates of Candida species. After 80 minutes exposure, about 50-90% inhibition of the viable cells was observed in all the tested isolates ( Figure 1 ). The bioconverted products of tomato completely inhibited the cell viable counts of C. albicans KBN06P00566 at 100 minutes exposure time. However, complete inhibition of C. albicans KBN06P00565, C. glabrata KBN06P00368, C. albicans KACC 30062 and C. albicans KACC 30004 was observed after 140 minutes exposure to the bioconverted products. C. albicans KCTC 7270 was found to be the least susceptible fungal pathogen to the bioconverted products. Previous findings confirmed that various bioconverted or microbial products displayed significant inhibitory effects on the viable counts of the tested fungal pathogens [9, 12, 14, 15] .
Hence, it is suggested that the bioconverted products of tomato can be used in a wide range of activities against Candida species, where these pathogens have developed resistance to specific fungicides [16] . In addition, bioconverted products of leptomycin B by a bacterial strain of Streptomyces sp. were able to exert significant anti-proliferative activity [17] . Confirmatory results on the production of antifungal materials through bioconversion using microorganisms have also been observed [11] .
The antimycotic effect of the bioconverted products of tomato on the morphology of a clinical isolate of C. glabrata KBN06P00368 was visualized by an elaborative SEM study. The bioconverted products altered the cell morphology when compared with the control group (Figure 2) . In contrast to the regular and smooth control cells (Figure 2a ), the cells inoculated with bioconverted products at the MIC concentration (250 μg/mL) revealed severe detrimental effects of the bioconverted products on the morphology of C. glabrata KBNP00368, showing disruption and swelling of the cells ( Figure  2b ) or even surface collapse and lysed cell formation (Figure 2c ). These altered morphological changes might occur due to the effect of the bioconverted products on membrane integrity, thereby resulting in the lysis of the cell wall, followed by loss of intracellular dense material on the surface of treated cells, as shown previously by others [11, 14] . Candida species accumulate phosphatidylserine with a lower proportion of phosphatidylcholine when treated with therapeutic antifungal agents. Changes in membrane fluidity usually occur due to alterations in membrane lipid composition [18, 19] , which are suspected to be a compensatory mechanism to counter the lipid disordering effects of the treatment agent.
In conclusion, this research demonstrated the potential antimycotic effect of microbially converted products of tomato by P. atrosepticum, inhibiting the growth of different clinical and pathogenic isolates of Candida species. The bioconverted products severely inhibited the growth of the tested clinical isolates. Although tomato has been associated with decreased risk of cancer and neurodegenerative diseases in human beings [20, 21] , there has been no research conducted so far using fermented tomato by P. atrosepticum for the production of new therapeutic agents of antimycotic efficacy. Several factors such as changes in seasonal patterns, weather events, temperature changes, and biotic and abiotic conditions may affect the production of secondary metabolites in plants, including the effect of pathogen interaction during the microbial bioconversion. Plant-microbe interaction might result in the production of potent biologically active biotranformation products during microbial conversion of tomato. It is also possible that during the microbial conversion, there might be some changes in the content of bioconverted products of tomato due to some molecular level alterations in the biosynthetic pathway of carotenoid production. Antimycotic effects of microbially bioconverted products against the pathogenic isolates of Candida species may offer new applications to antimycotic therapy. Hence, the bioconverted products obtained from the microbial conversion of tomato by P. atrosepticum could serve as an alternative biomedicinal product in pharmaceutical bioformulations for their possible antifungal and antimycotic applications. Here it is suggested that if this newly developed technology is going to be a practical approach, there could be a high medicinal and economic potential of microbially bioconverted vegetable products in future. The effect of geographical variations on the content of bioconverted products of various tomato cultivars from different locations still need to be studied. 
Substrate and microbial conversion:
As a substrate, red mature tomatoes were purchased from the local market in Gyeongsan City, Gyeongbuk, Republic of Korea. For microbial bioconversion, tomato fruits were surface sterilized with 70% ethanol, and further washed 3 times with distilled water to remove any superficial microbial load. Adhering water contents were dried to avoid any microbial contamination. Around 300 g of tomato fruit was crushed into small pieces using a sterilized knife. For microbial conversion, contamination-free substrate tomato samples were inoculated with 30 mL of P. atrosepticum at 0.5 OD 600 grown for 24 h in 500 mL Erlenmeyer flasks, and then continuously incubated for 7 days at 200 rpm in a Psycro Therm controlled environment shaker (Model: VS 8480, Vision Scientific Co. Ltd., Republic of Korea) at 28 o C. After conversion of the substrate tomato samples by P. atrosepticum, the supernatant and pellet were separated by centrifugation. The pellet was discarded and the collected supernatant layer was immediately extracted twice with ethyl acetate to kill the culture. The bioconverted products were obtained, and evaporation of the solvent from the combined extract of bioconverted products was accomplished using a rotary evaporator (EYELA N1000, Japan). All chemicals and solvents used were of analytical grade with over 99.5% purity (Merck, Inc., Germany).
Antimycotic activity assay:
The standard agar diffusion method was used to determine the antimycotic activity of microbially bioconverted products of tomato [22] . A 100 μL of standardized inoculum containing 10 7 CFU/mL of fungal suspension was loaded uniformly onto Petri plates with 20 mL of potato-dextrose agar (PDA) medium, and allowed to dry for 5 min. A sterile Whatman No. 1 filter paper disc with 6 mm diameter was impregnated with 500 μg/disc of bioconverted products of tomato, which were dissolved in the same solvent (ethyl acetate) used for the extraction of bioconverted products. Controls were composed of the supernatants of crushed tomato fruits and the tomato fermented for 7 days alone. Negative controls were prepared using the same solvent (ethyl acetate) employed to dissolve the dried supernatant of crushed tomato fruits, as well as the supernatants of 24 h and 7 day grown cultures of P. atrosepticum. Amphotericin B (10 μg/disc, Sigma-Aldrich Co., St. Louis, MO, USA) was used as the positive control for the tested isolates. After incubating the plates at 28ºC for 2 -3 days, antimycotic activity was evaluated by comparing the diameters of zones of inhibition. For the antifungal activity assay, the experiment was replicated at least 3 times.
Minimum inhibitory (MIC) and minimum fungicidal (MFC) concentrations:
A method of two-fold serial dilution was employed to determine the MIC values of the bioconverted products of tomato [23] . The bioconverted products, dissolved in 5% dimethyl sulfoxide, were incorporated into PDB medium to obtain a concentration of 4000 μg/mL, and then serially diluted to achieve 2000, 1000, 500, 250, 125, 62.5, 31.25, 15.62 and 7.81 μg/mL, respectively. A 10 μL standardized suspension of each test Candida species (10 7 CFU/mL approximately) was transferred to each tube. The control tubes, with only candidal suspension, were incubated at 28 o C for 2 -3 days. MIC, expressed in μg/mL, was defined as the lowest concentration of the bioconverted products not showing any growth of test Candida species by macroscopic evaluation. The concentrations showing complete inhibition of visual growth of fungal isolates were identified, and 50 μL of each diluted culture broth transferred to the agar plates. The plates were incubated for the specified time and at the temperature mentioned above. The complete absence of growth on the agar surface in the lowest concentration of sample was defined as MFC.
Cell viability assay:
For viable count assay, each of the tubes containing re-suspended candidal suspension (approximately 10 7 CFU/mL) was inoculated with 500 μg/mL of the bioconverted products of tomato in 10 mL PDB broth, and incubated at 28ºC [9] . For viable cell counts, samples were taken at 0, 20, 40, 60, 80, 100 and 140 min time intervals, and the viable cells were counted as followed: After incubation for a specified time, 1 mL of the resuspended culture was diluted with 9 mL buffer peptone water, thereby diluting it 10-fold. A 0.1 mL sample of each treatment was diluted further and spread on the surface of PDA agar media. Newly formed colonies were counted after 2 -3 days of incubation at 28ºC. The controls were composed of inoculums without bioconverted products of tomato for each Candida isolate with the same experimental conditions. Each assay was replicated 3 times.
Scanning electron microscopy (SEM):
To determine the antimycotic efficacy of the bioconverted product of tomato on the morphology of C. glabrata KBN06P00368, SEM was performed using the MIC of the bioconverted products of tomato. Controls were prepared without the bioconverted product. To observe the morphological changes, the method of SEM was modified from Kockro's method [24] . The fungal samples were washed gently with 0.1M phosphate buffer solution (pH 7.2), and then fixed with 2.5% (w/v) glutaraldehyde. The specimen was dehydrated using sequential exposure with ethanol concentrations ranging from 50 to 100%, and then with tertiary butyl alcohol. After dehydration, the Antimycotic bioconverted products of tomato by P. atrosepticum Natural Product Communications Vol. 7 (1) 2012 69 specimen was dried with CO 2 . Finally, the specimen was sputtercoated with gold in an ion coater for 2 min, followed by SEM examinations (S-4300; Hitachi, Japan).
Statistical analysis:
Each experiment was performed in triplicate and the average values were calculated. Statistical analysis was carried out employing one way ANOVA (p < 0.05) with a SPSS statistical package (version 11.0).
